Your session is about to expire
← Back to Search
Vasodilator
A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis
Phase 2
Waitlist Available
Research Sponsored by Bellerophon
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion; an average of 1 year
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a treatment where patients breathe in short bursts of nitric oxide gas. It is aimed at people with lung diseases like pulmonary fibrosis or sarcoidosis who need long-term oxygen therapy. The treatment helps improve blood flow in the lungs, making it easier for these patients to breathe.
Eligible Conditions
- Pulmonary Fibrosis
- Pulmonary Sarcoidosis
- Pulmonary Hypertension
- Sarcoidosis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion; an average of 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion; an average of 1 year
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in 6MWD from Baseline to 16 Weeks
Measurement of CO
Measurement of PCWP
+2 moreSecondary study objectives
Distance Saturation Product (DSP)
Dyspnea
Incidence and Severity of Treatment Emergent Adverse Events
+4 moreSide effects data
From 2021 Phase 4 trial • 519 Patients • NCT0308105228%
Venous Thromboemolic DVT
13%
Venous Thromboembolic Other
11%
New Onset Atrial Fibrillation
9%
All Cause Mortality
6%
Arterial Thromboembolic CVA/Stroke
5%
Venous Thromboembolic PE
3%
Arterial Thromboembolic Mesenteric Ischemia
2%
Arterial Thromboembolic Myocardial Infarction
2%
Upper GI Bleed
1%
Lower GI Bleed
100%
80%
60%
40%
20%
0%
Study treatment Arm
Lung Transplant With iNO
Lung Transplant With iEPO
Heart Transplant & LVAD Implantation With iNO
Heart Transplant & LVAD Implantation With iEPO
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: PH-SarcoidosisExperimental Treatment1 Intervention
Part 1: 1st 4 subjects will be treated with iNO 30, 45, 75 mcg/kg IBW/hr
2nd 4 subjects will be treated with iNO 45, 75, 125 mcg/kg IBW/hr
Part 2: Optional Open label long term extension at the optimal dose as identified in Part 1
Group II: PH-Pulmonary FibrosisExperimental Treatment1 Intervention
Part 1: 1st 4 subjects will be treated with iNO 30, 45, 75 mcg/kg IBW/hr
2nd 4 subjects will be treated with iNO 45, 75, 125 mcg/kg IBW/hr
Part 2: Optional open label long term extension at the optimal dose as identified in Part 1
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
iNO
2011
Completed Phase 4
~1370
Find a Location
Who is running the clinical trial?
BellerophonLead Sponsor
7 Previous Clinical Trials
210 Total Patients Enrolled
3 Trials studying Pulmonary Fibrosis
93 Patients Enrolled for Pulmonary Fibrosis
Edward Parsley, DOStudy DirectorBellerophon Pulse Technologies
2 Previous Clinical Trials
336 Total Patients Enrolled
1 Trials studying Pulmonary Fibrosis
145 Patients Enrolled for Pulmonary Fibrosis